A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.
Identifieur interne : 000323 ( PubMed/Curation ); précédent : 000322; suivant : 000324A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.
Auteurs : Maribel Márquez-Cruz [Mexique] ; Juan Pablo Díaz-Martínez [Canada] ; Herman Soto-Molina [Mexique] ; Adib Jorge De Saráchaga [Mexique] ; Amin Cervantes-Arriaga [Mexique] ; Rodrigo Llorens-Arenas [Mexique] ; Mayela Rodríguez-Violante [Mexique]Source :
- Expert review of pharmacoeconomics & outcomes research [ 1744-8379 ] ; 2016.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Antiparkinson Agents.
- chemical , therapeutic use : Antiparkinson Agents.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Drug Therapy, Combination, Humans, Latin America, Models, Statistical, Randomized Controlled Trials as Topic, Treatment Outcome.
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease. There are no clinical trials comparing all available pharmacological therapies for the treatment of early PD. The objective of this review is to indirectly analyze the efficacy of antiparkinson drugs currently available in Latin America. A systematic review was performed exploring only placebo-controlled randomized trials comparing antiparkinson monotherapy (levodopa, pramipexole, rasagiline, or selegiline) in patients with PD on Hoehn and Yahr stages I through III published from January 1994 to May 2014. The primary outcome was the mean change in the Unified PD Rating Scale (UPDRS) I, II and III. A mixed treatment comparison analysis (indirect comparisons) through a random-effects model was performed. Levodopa demonstrated the highest effects in terms of UPDRS score improvement both from baseline and when compared to other treatments. Levodopa showed a 60.1% probability of granting the greatest reduction in UPDRS I, II and III.
DOI: 10.1586/14737167.2016.1135740
PubMed: 26731410
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000323
Links to Exploration step
pubmed:26731410Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.</title><author><name sortKey="Marquez Cruz, Maribel" sort="Marquez Cruz, Maribel" uniqKey="Marquez Cruz M" first="Maribel" last="Márquez-Cruz">Maribel Márquez-Cruz</name><affiliation wicri:level="1"><nlm:affiliation>a Universidad Autónoma Metropolitana, Unidad Xochimilco , Mexico City , Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>a Universidad Autónoma Metropolitana, Unidad Xochimilco , Mexico City </wicri:regionArea></affiliation></author><author><name sortKey="Diaz Martinez, Juan Pablo" sort="Diaz Martinez, Juan Pablo" uniqKey="Diaz Martinez J" first="Juan Pablo" last="Díaz-Martínez">Juan Pablo Díaz-Martínez</name><affiliation wicri:level="1"><nlm:affiliation>b McMaster University , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>b McMaster University , Ontario </wicri:regionArea></affiliation></author><author><name sortKey="Soto Molina, Herman" sort="Soto Molina, Herman" uniqKey="Soto Molina H" first="Herman" last="Soto-Molina">Herman Soto-Molina</name><affiliation wicri:level="1"><nlm:affiliation>a Universidad Autónoma Metropolitana, Unidad Xochimilco , Mexico City , Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>a Universidad Autónoma Metropolitana, Unidad Xochimilco , Mexico City </wicri:regionArea></affiliation></author><author><name sortKey="De Sarachaga, Adib Jorge" sort="De Sarachaga, Adib Jorge" uniqKey="De Sarachaga A" first="Adib Jorge" last="De Saráchaga">Adib Jorge De Saráchaga</name><affiliation wicri:level="1"><nlm:affiliation>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City </wicri:regionArea></affiliation></author><author><name sortKey="Cervantes Arriaga, Amin" sort="Cervantes Arriaga, Amin" uniqKey="Cervantes Arriaga A" first="Amin" last="Cervantes-Arriaga">Amin Cervantes-Arriaga</name><affiliation wicri:level="1"><nlm:affiliation>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City </wicri:regionArea></affiliation></author><author><name sortKey="Llorens Arenas, Rodrigo" sort="Llorens Arenas, Rodrigo" uniqKey="Llorens Arenas R" first="Rodrigo" last="Llorens-Arenas">Rodrigo Llorens-Arenas</name><affiliation wicri:level="1"><nlm:affiliation>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City </wicri:regionArea></affiliation></author><author><name sortKey="Rodriguez Violante, Mayela" sort="Rodriguez Violante, Mayela" uniqKey="Rodriguez Violante M" first="Mayela" last="Rodríguez-Violante">Mayela Rodríguez-Violante</name><affiliation wicri:level="1"><nlm:affiliation>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City </wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26731410</idno><idno type="pmid">26731410</idno><idno type="doi">10.1586/14737167.2016.1135740</idno><idno type="wicri:Area/PubMed/Corpus">000323</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000323</idno><idno type="wicri:Area/PubMed/Curation">000323</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000323</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.</title><author><name sortKey="Marquez Cruz, Maribel" sort="Marquez Cruz, Maribel" uniqKey="Marquez Cruz M" first="Maribel" last="Márquez-Cruz">Maribel Márquez-Cruz</name><affiliation wicri:level="1"><nlm:affiliation>a Universidad Autónoma Metropolitana, Unidad Xochimilco , Mexico City , Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>a Universidad Autónoma Metropolitana, Unidad Xochimilco , Mexico City </wicri:regionArea></affiliation></author><author><name sortKey="Diaz Martinez, Juan Pablo" sort="Diaz Martinez, Juan Pablo" uniqKey="Diaz Martinez J" first="Juan Pablo" last="Díaz-Martínez">Juan Pablo Díaz-Martínez</name><affiliation wicri:level="1"><nlm:affiliation>b McMaster University , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>b McMaster University , Ontario </wicri:regionArea></affiliation></author><author><name sortKey="Soto Molina, Herman" sort="Soto Molina, Herman" uniqKey="Soto Molina H" first="Herman" last="Soto-Molina">Herman Soto-Molina</name><affiliation wicri:level="1"><nlm:affiliation>a Universidad Autónoma Metropolitana, Unidad Xochimilco , Mexico City , Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>a Universidad Autónoma Metropolitana, Unidad Xochimilco , Mexico City </wicri:regionArea></affiliation></author><author><name sortKey="De Sarachaga, Adib Jorge" sort="De Sarachaga, Adib Jorge" uniqKey="De Sarachaga A" first="Adib Jorge" last="De Saráchaga">Adib Jorge De Saráchaga</name><affiliation wicri:level="1"><nlm:affiliation>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City </wicri:regionArea></affiliation></author><author><name sortKey="Cervantes Arriaga, Amin" sort="Cervantes Arriaga, Amin" uniqKey="Cervantes Arriaga A" first="Amin" last="Cervantes-Arriaga">Amin Cervantes-Arriaga</name><affiliation wicri:level="1"><nlm:affiliation>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City </wicri:regionArea></affiliation></author><author><name sortKey="Llorens Arenas, Rodrigo" sort="Llorens Arenas, Rodrigo" uniqKey="Llorens Arenas R" first="Rodrigo" last="Llorens-Arenas">Rodrigo Llorens-Arenas</name><affiliation wicri:level="1"><nlm:affiliation>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City </wicri:regionArea></affiliation></author><author><name sortKey="Rodriguez Violante, Mayela" sort="Rodriguez Violante, Mayela" uniqKey="Rodriguez Violante M" first="Mayela" last="Rodríguez-Violante">Mayela Rodríguez-Violante</name><affiliation wicri:level="1"><nlm:affiliation>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City </wicri:regionArea></affiliation></author></analytic><series><title level="j">Expert review of pharmacoeconomics & outcomes research</title><idno type="eISSN">1744-8379</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Latin America</term><term>Models, Statistical</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Randomized Controlled Trials as Topic</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Therapy, Combination</term><term>Humans</term><term>Latin America</term><term>Models, Statistical</term><term>Randomized Controlled Trials as Topic</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is the second most common neurodegenerative disease. There are no clinical trials comparing all available pharmacological therapies for the treatment of early PD. The objective of this review is to indirectly analyze the efficacy of antiparkinson drugs currently available in Latin America. A systematic review was performed exploring only placebo-controlled randomized trials comparing antiparkinson monotherapy (levodopa, pramipexole, rasagiline, or selegiline) in patients with PD on Hoehn and Yahr stages I through III published from January 1994 to May 2014. The primary outcome was the mean change in the Unified PD Rating Scale (UPDRS) I, II and III. A mixed treatment comparison analysis (indirect comparisons) through a random-effects model was performed. Levodopa demonstrated the highest effects in terms of UPDRS score improvement both from baseline and when compared to other treatments. Levodopa showed a 60.1% probability of granting the greatest reduction in UPDRS I, II and III.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26731410</PMID><DateCreated><Year>2016</Year><Month>02</Month><Day>13</Day></DateCreated><DateCompleted><Year>2016</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8379</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Expert review of pharmacoeconomics & outcomes research</Title><ISOAbbreviation>Expert Rev Pharmacoecon Outcomes Res</ISOAbbreviation></Journal><ArticleTitle>A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.</ArticleTitle><Pagination><MedlinePgn>97-102</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1586/14737167.2016.1135740</ELocationID><Abstract><AbstractText>Parkinson's disease (PD) is the second most common neurodegenerative disease. There are no clinical trials comparing all available pharmacological therapies for the treatment of early PD. The objective of this review is to indirectly analyze the efficacy of antiparkinson drugs currently available in Latin America. A systematic review was performed exploring only placebo-controlled randomized trials comparing antiparkinson monotherapy (levodopa, pramipexole, rasagiline, or selegiline) in patients with PD on Hoehn and Yahr stages I through III published from January 1994 to May 2014. The primary outcome was the mean change in the Unified PD Rating Scale (UPDRS) I, II and III. A mixed treatment comparison analysis (indirect comparisons) through a random-effects model was performed. Levodopa demonstrated the highest effects in terms of UPDRS score improvement both from baseline and when compared to other treatments. Levodopa showed a 60.1% probability of granting the greatest reduction in UPDRS I, II and III.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Márquez-Cruz</LastName><ForeName>Maribel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>a Universidad Autónoma Metropolitana, Unidad Xochimilco , Mexico City , Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Díaz-Martínez</LastName><ForeName>Juan Pablo</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>b McMaster University , Ontario , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soto-Molina</LastName><ForeName>Herman</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>a Universidad Autónoma Metropolitana, Unidad Xochimilco , Mexico City , Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Saráchaga</LastName><ForeName>Adib Jorge</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervantes-Arriaga</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llorens-Arenas</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>d Movement Disorder Clinic , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodríguez-Violante</LastName><ForeName>Mayela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>c Clinical Neurodegenerative Research Unit , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>d Movement Disorder Clinic , National Institute of Neurology and Neurosurgery , Mexico City , Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Pharmacoecon Outcomes Res</MedlineTA><NlmUniqueID>101132257</NlmUniqueID><ISSNLinking>1473-7167</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007843" MajorTopicYN="N">Latin America</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="Y">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson’s disease</Keyword><Keyword MajorTopicYN="N">indirect comparisons</Keyword><Keyword MajorTopicYN="N">random-effects model</Keyword><Keyword MajorTopicYN="N">randomized controlled trials</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26731410</ArticleId><ArticleId IdType="doi">10.1586/14737167.2016.1135740</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000323 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000323 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26731410
|texte= A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26731410" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |